Incendia Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States11-50 Employees

Incendia Therapeutics is a small- to mid-sized, clinical-stage biotechnology company based in Cambridge, Massachusetts. It focuses on discovering and developing monoclonal antibody therapies that disrupt the tumor microenvironment to improve cancer outcomes, with an emphasis on immune-excluded solid tumors where barriers limit immune cell infiltration and therapeutic reach.

The company's lead program, PRTH-101, is a novel antibody that binds to and inhibits DDR1, an element of the tumor microenvironment expressed by cancer cells across multiple solid tumor types, and the firm is enrolling patients in a Phase 1c trial for advanced solid tumors including thymic carcinoma. In October 2024, Delfi Diagnostics announced a partnership with Incendia to apply an advanced treatment-monitoring test within the ongoing Phase 1 trial.

Sign up for free to view info

Company overview Employee directory